Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors Including Central Nervous System Tumors

  • STATUS
    Recruiting
  • End date
    May 31, 2022
  • participants needed
    120
  • sponsor
    Eisai Inc.
Updated on 25 June 2020
Investigator
Eisai Medical Information
Primary Contact
Children's National Medical Center (5.4 mi away) Contact
+54 other location

Summary

Phase 1 of this study, utilizing a rolling 6 design, will be conducted to determine a maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and to describe the toxicities of lenvatinib administered in combination with everolimus once daily to pediatric participants with recurrent/refractory solid tumors. Phase 2, utilizing Simon's optimal 2-stage design, will be conducted to estimate the antitumor activity of lenvatinib in combination with everolimus in pediatric participants with selected recurrent/refractory solid tumors including Ewing sarcoma/peripheral primitive neuroectodermal tumor (pPNET), rhabdomyosarcoma, and high grade glioma (HGG) using objective response rate (ORR) at Week 16 as the outcome measure.

Details
Treatment Everolimus, Lenvatinib
Clinical Study IdentifierNCT03245151
SponsorEisai Inc.
Last Modified on25 June 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 2 yrs and 21 yrs?
Gender: Male or Female
Do you have Recurrent and Refractory Solid Tumors?
years and <18 years of age for enrolment in Phase 1 or 2 years and 21 years of age for enrolment in Phase 2
Recurrent or refractory solid tumors
Phase 1: All solid tumors (measurable or evaluable disease), including primary central nervous system (CNS) tumors; exclusion of hepatoblastoma and lymphomas. Participants with diffuse intrinsic pontine glioma, optic pathway glioma, or pineal tumors with elevated tumor markers (alpha-fetoprotein [AFP] and beta-human chorionic gonadotropin [-hCG][or human chorionic gonadotropin [hCG])do not require histological or cytological confirmation of diagnosis
Phase 2: Ewing sarcoma/peripheral primitive neuroectodermal tumor (pPNET), Rhabdomyosarcoma, High Grade Glioma (HGG) (all must have measurable disease); exclusion of Diffuse Intrinsic Pontine Glioma
Histologically or cytologically confirmed diagnosis
Measurable disease that meets the following criteria (Phase 2)
RECIST 1.1 (for all tumor types except HGG): At least 1 lesion of 1.0 cm in the longest diameter for a non lymph node or 1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST 1.1 using computed tomography /magnetic resonance imaging (CT/MRI)
Response Assessment in Neuro-Oncology (RANO) for high grade glioma (HGG): At least one lesion must be measurable as defined as a bi dimensionally contrast enhancing lesion with clearly defined margins by CT or MRI scan, with a minimal diameter of 1 cm, and visible on 2 axial slices which are preferably at most 5 mm apart with 0 mm skip
Lesions that have had external beam radiotherapy (EBRT) or locoregional
therapies such as radiofrequency (RF) ablation must show evidence of
progressive disease based on RECIST 1.1 to be deemed a target lesion
Karnofsky performance score 50 for participants>16 year of age and Lansky play score 50 for participants 16 years of age. Neurologic deficits in participants with CNS tumors must have been relatively stable for at least 7 days prior to study enrollment. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
Prior Therapy
Participants must have fully recovered from the acute toxic effects of all prior anti-cancer therapy
Cytotoxic chemotherapy or other chemotherapy known to be myelosuppressive: 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)
Anti-cancer agents not known to be myelosuppressive (eg, not associated with reduced platelet or absolute neutrophil counts): 7 days after the last dose of agent
Monoclonal antibodies: 21 days or 3 half-lives (whichever is shorter) of the antibody must have elapsed after the last dose of a monoclonal antibody (including checkpoint inhibitors). Toxicity related to prior antibody therapy must be recovered to Grade 1
Corticosteroids: If used to modify immune adverse events related to prior therapy, 14 days must have elapsed since last dose of corticosteroid. Participants receiving corticosteroids, who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment, are not eligible
Hematopoietic growth factors: 14 days after the last dose of a long-acting growth factor or 7 days for short-acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur
Interleukins, interferons, and cytokines (other than hematopoietic growth factors): 21 days after the completion of interleukins, interferons or cytokines (other than hematopoietic growth factors)
Stem cell infusions (with or without total body irradiation): Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor leukocytes infusion or boost infusion: 84 days after infusion and no evidence of graft versus host disease; Autologous stem cell infusion including boost infusion: 42 days
Cellular Therapy: 42 days after the completion of any type of cellular therapy (eg, modified T cells, natural killer cells, dendritic cells, etc)
Radiotherapy (XRT)/External Beam Irradiation including Protons: 14 days after local XRT; 150 days after total body irradiation, craniospinal XRT or if radiation to 50% of the pelvis; 42 days if other substantial bone marrow radiation
Radiopharmaceutical therapy: 42 days after systemically administered therapy
Vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)-targeted or mammalian target of rapamycin (mTOR)-targeted therapies: Must not have received prior exposure to lenvatinib; May have previously progressed on an mTOR inhibitor; No more than 2 prior VEGF/VEGFR-targeted therapies (For Phase 2 only); Must not have received prior VEGF/VEGFR-targeted therapy in combination with an mTOR inhibitor (For Phase 2 only)
Adequate bone marrow function for participants with solid tumors without known bone marrow involvement
Adequate bone marrow function for participants with known bone marrow metastatic disease
Adequate renal function
Adequate liver function
Adequate cardiac function
Adequate neurologic function
Adequate blood pressure (BP) control with or without antihypertensive medications
Adequate coagulation
Adequate pancreatic function
Adequate metabolic function
Adequate glycemic control
Participants must have a minimum body surface area (BSA) of 0.6 m^2 at study entry

Exclusion Criteria

Participants who have had or are planning to have the following invasive procedures
Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrolment
Central line placement or subcutaneous port placement is not considered major surgery. External central lines must be placed at least 3 days prior to enrollment and subcutaneous ports must be placed at least 7 days prior to enrollment
Fine needle aspirate within 7 days prior to enrolment
Surgical or other wounds must be adequately healed prior to enrolment
For purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapy
Participants who have non-healing wound, unhealed or incompletely healed fracture, or a compound (open) bone fracture at the time of enrolment
Participants having an active infection requiring systemic therapy
Participants with a known history of active hepatitis B (defined as hepatitis B surface antigen reactive or hepatitis B virus- deoxyribonucleic [DNA] detected) or known active hepatitis C virus (HCV, defined as HCV- Ribonucleic acid [RNA] detected). Note: No testing for hepatitis B and hepatitis C is required unless mandated by the local health authority
Known to be human immunodeficiency virus (HIV) positive. Note: HIV testing is required at screening only when mandated by the local health authority
Clinical evidence of nephrotic syndrome prior to enrolment
Gastrointestinal bleeding or active hemoptysis (bright red blood of at least half teaspoon) within 21 days prior to enrolment
Thrombotic/ thromboembolic event requiring systemic anticoagulation within 90 days prior to enrollment
Evidence of new intracranial hemorrhage of more than punctate size on MRI assessment obtained within 28 days prior to study enrollment for Participants with HGG
Diagnosis of lymphoma
Radiographic evidence of major blood vessel invasion/infiltration
Evidence of untreated CNS metastases (exception: participants with primary CNS tumors and leptomeningeal disease)
Participants who are currently receiving enzyme-inducing anticonvulsants
Participants chronically receiving strong cytochrome P450 3A4 (CYP3A4)/P-glycoprotein (P-gp) inhibitors or inducers within 7 days prior to study enrollment
Females who are breastfeeding or pregnant. For females of childbearing potential, a negative screening pregnancy test must be obtained within 72 hours before the first dose of study drug
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet